ArticleCell reports2014
Path to the clinic: assessment of iPSC-based cell therapies in vivo in a nonhuman primate model.
Article in Cell reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Induced pluripotent stem cells as a new getaway for bone tissue engineering: A systematic review.Cell proliferation · 2017Pooled it
- Multidimensional bibliometric analysis and global trends in the nervous system's role in bone regeneration.Regenerative therapy · 2026Article
- Replicable generation and stable maintenance of rhesus macaque iPSCs forFrontiers in cell and developmental biology · 2026Article
- Engineering of rhesus monkey pluripotent stem cells for noninvasive survey and remote control after brain allotransplantation.Fundamental research · 2026Article
- Non-human primate preclinical model revealed the feasibility and short-term safety of iPSC-derived innate-like T cells in autologous transplantation.Frontiers in immunology · 2025Article
- Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies.International journal of surgery (London, England) · 2024Review
- Long-term engraftment and maturation of autologous iPSC-derived cardiomyocytes in two rhesus macaques.Cell stem cell · 2024Article
- Label-Free and High-Throughput Removal of Residual Undifferentiated Cells From iPSC-Derived Spinal Cord Progenitor Cells.Stem cells translational medicine · 2024Article
- Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques.Nature biotechnology · 2024Article
- Stem Cells and Bone Tissue Engineering.Life (Basel, Switzerland) · 2024Review
- Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.Current medicinal chemistry · 2024Review
- Generation of induced pluripotent stem cells from the Asian bats.International journal of veterinary science and medicine · 2024Article
- Hepatobiliary organoids differentiated from hiPSCs relieve cholestasis-induced liver fibrosis in nonhuman primates.International journal of biological sciences · 2024Article
- Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.Molecular cancer · 2023Review
- The evolution of aging and lifespan.Trends in genetics : TIG · 2023Review
- Subcutaneous transplantation of human embryonic stem cells-derived pituitary organoids.Frontiers in endocrinology · 2023Article
- Tissue-Engineered Models of the Human Brain: State-of-the-Art Analysis and Challenges.Journal of functional biomaterials · 2022Review
- Stem cell therapy as a promising strategy in necrotizing enterocolitis.Molecular medicine (Cambridge, Mass.) · 2022Review
- Generation of macrophages with altered viral sensitivity from genome-edited rhesus macaque iPSCs to model human disease.Molecular therapy. Methods & clinical development · 2021Article
- Novel cell sources for bone regeneration.MedComm · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Induced pluripotent stem cell (iPSC)-based cell therapies have great potential for regenerative medicine but are also potentially associated with tumorigenic risks. Current rodent models are not optimal predictors of efficiency and safety for clinical application. Therefore, we developed a clinically relevant nonhuman primate model to assess the tumorigenic potential and in vivo efficacy of both undifferentiated and differentiated iPSCs in autologous settings without immunosuppression. Undifferentiated autologous iPSCs indeed form mature teratomas in a dose-dependent manner. However, tumor formation is accompanied by an inflammatory reaction. On the other hand, iPSC-derived mesodermal stromal-like cells form new bone in vivo without any evidence of teratoma formation. We therefore show in a large animal model that closely resembles human physiology that undifferentiated autologous iPSCs form teratomas, and that iPSC-derived progenitor cells can give rise to a functional tissue in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.